200th Institution Joins Kerafast as a Provider We are excited to announce our 200th providing institution, King Abdullah University of Science and Technology (KAUST). This is a significant milestone, as Kerafast, founded in 2011, continues to grow a portfolio of unique reagents contributed by researchers worldwide and easily accessible to the global scientific community. KAUST is Kerafast’s first institution in the Middle East and North Africa, with plans to offer a collection of novel peptides and peptide scaffolds in our reagents catalog. Read the full press release and check out our blog post to learn more about KAUST and our partnership.
The Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies Our provider, Dr. Brain Geiss from Colorado State University, recently wrote an article highlighting the development of the SARS-CoV-2 nucleocapsid specific monoclonal antibodies which are available for purchase in the Kerafast catalog here. The publication concludes that there is strong evidence for the specificity and utility of the SARS-CoV-2 specific monoclonal antibodies for studying the SARS-CoV-2 N protein. It’s always exciting to see our providers’ research, especially when it features a reagent in our catalog. Don’t hesitate to contact us if you have a research study that we could feature.
Summer 2021 Company Outing It has been a long time since our whole Boston office has been able to come together and celebrate our achievements and hard work due to COVID restrictions. However, this August we celebrated a successful summer with a boat cruise around Boston! The office’s collective efforts have continued to help grow Kerafast and our sister company Absolute Antibody. We look forward to more in-person office activities and the continued company growth as we finish out the year. It’s always fun to get everyone together and enjoy a beautiful day on the water!
Featured Lab
Zhi-Ming Zheng, MD, PhD, Nation Cancer Institute/NIH The Zheng laboratory studies protein-RNA interactions and their consequences in various infections with tumor viruses. They aim to understand how RNA splicing and small regulatory RNAs regulate the __expression__ of viral and host genes in viral carcinogenesis. The long-term goal is to develop a series of therapeutic approaches to control viral or cellular gene __expression__ for cancer treatment and to identify biomarkers for clinical diagnosis and prognosis. Dr. Zheng offers a SRp20 Expressing Tumorigenic MEF/3T3 Tet-Off Cell Line in our reagents catalog.
Blast from the Past Contest Winners This past quarter, we invited our community of scientists with years of research experience to submit a blog post about their first research project and the influence it had on their career. We are excited to share that the winners are Dr. Jared Barrott from Idaho State University and Dr. Sathya Puthanveettil from the Scripps Research Institute. They both wrote about their first research project, which you can read on our blog, and won a $1,250 gift card as the contest winners. Keep an eye out for our next quarterly contest for a chance to enter and win!
We are excited to announce our 200th providing institution, King Abdullah University of Science and Technology (KAUST). This is a significant milestone, as Kerafast, founded in 2011, continues to grow a portfolio of unique reagents contributed by researchers worldwide and easily accessible to the global scientific community. KAUST is Kerafast’s first institution in the Middle East and North Africa, with plans to offer a collection of novel peptides and peptide scaffolds in our reagents catalog. Read the full 
Our provider, 
The Zheng laboratory studies protein-RNA interactions and their consequences in various infections with tumor viruses. They aim to understand how RNA splicing and small regulatory RNAs regulate the __expression__ of viral and host genes in viral carcinogenesis. The long-term goal is to develop a series of therapeutic approaches to control viral or cellular gene __expression__ for cancer treatment and to identify biomarkers for clinical diagnosis and prognosis. Dr. Zheng offers a 
This past quarter, we invited our community of scientists with years of research experience to submit a blog post about their first research project and the influence it had on their career. We are excited to share that the winners are 
